BIOTRON LIMITED - Announcements

25.0%

0.3¢

Market Cap $3.318M

Healthcare Biotechnology

Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the... Biotron Limited is a clinical-stage biotechnology company. The Company is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and COVID-19, and additional preclinical programs including Hepatitis B Virus (HBV). In addition, the Company has several early-stage programs designing drugs that target a class of virus protein known as viroporins, which have a key role in the virus life cycle of a range of viruses, such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses. Its proprietary primary bacterial cell-based screening platform enables rapid screening of target viroporin proteins. Its lead compound, BIT225, is in Phase II development for the treatment of HIV-1. The Company also has a portfolio of preclinical antiviral programs.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/25	365.37KB	Share
BIT	Hepatitis B Virus Program Update	PRICE SENSITIVE	24/06/25	138.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/25	349.8KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	08/04/25	133.63KB	Share
BIT	Replacement Prospectus	PRICE SENSITIVE	12/03/25	385.48KB	Share
BIT	Response to ASX Query Letter	PRICE SENSITIVE	12/03/25	374.05KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	05/03/25	68.87KB	Share
BIT	Response to ASX Aware Query	PRICE SENSITIVE	04/03/25	1.06MB	Share
BIT	Prospectus	PRICE SENSITIVE	03/03/25	480.48KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	766.57KB	Share
BIT	Renounceable Rights Issue	PRICE SENSITIVE	28/02/25	162.83KB	Share
BIT	Updated Appendix 4C	PRICE SENSITIVE	03/02/25	169.95KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/25	393.34KB	Share
BIT	Agreement with C14 Consulting Group	PRICE SENSITIVE	27/11/24	168.55KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/24	1.07MB	Share
BIT	$1.8M R&D Rebate Received	PRICE SENSITIVE	14/10/24	399.28KB	Share
BIT	Response to ASX Aware Query	PRICE SENSITIVE	25/09/24	1.5MB	Share
BIT	BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL	PRICE SENSITIVE	06/09/24	540.68KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	30/08/24	1.41MB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	1.01MB	Share
BIT	BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives	PRICE SENSITIVE	19/06/24	711.16KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/04/24	1MB	Share
BIT	POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV	PRICE SENSITIVE	05/04/24	670.99KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	27/03/24	453.67KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/24	603.88KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/24	277.88KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	1.03MB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	29/09/23	712.55KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	11/09/23	665.15KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	25/08/23	1.05MB	Share
BIT	COMPLETION OF PHASE 2 COVID CLINICAL TRIAL	PRICE SENSITIVE	16/08/23	312.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	475.77KB	Share
BIT	Second Site Approved for Phase 2 Covid-19 Trial	PRICE SENSITIVE	12/05/23	89.11KB	Share
BIT	Commencement Phase 2 Covid-19 Clinical Trial	PRICE SENSITIVE	04/05/23	144.72KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	1.01MB	Share
BIT	Completion of Phase 2 HIV-1 Clinical Trials	PRICE SENSITIVE	09/03/23	403.58KB	Share
BIT	International Presentation of BIT225 COVID-19 Data	PRICE SENSITIVE	21/02/23	824.33KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	17/02/23	794.46KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	436.71KB	Share
BIT	Rights Issue Closed	PRICE SENSITIVE	24/11/22	174.24KB	Share
BIT	Supplementary Prospectus	PRICE SENSITIVE	24/11/22	139.65KB	Share
BIT	$1.43M R&D rebate received	PRICE SENSITIVE	18/11/22	148.2KB	Share
BIT	Commencement of Rights Trading - BITRC	PRICE SENSITIVE	31/10/22	128.29KB	Share
BIT	Prospectus	PRICE SENSITIVE	27/10/22	683.43KB	Share
BIT	Renounceable Issue	PRICE SENSITIVE	27/10/22	190.28KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/10/22	422.98KB	Share
BIT	Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	04/10/22	181.16KB	Share
BIT	Bit225 Covid-19 Human Study Commenced	PRICE SENSITIVE	14/09/22	175.41KB	Share
BIT	BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited	PRICE SENSITIVE	23/08/22	154.11KB	Share
BIT	Full Year Statutory Accounts and Appendix 4E	PRICE SENSITIVE	19/08/22	670.98KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/22	1.04MB	Share
BIT	POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM	PRICE SENSITIVE	30/05/22	130.47KB	Share
BIT	BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS	PRICE SENSITIVE	02/05/22	353.01KB	Share
BIT	Quarterly Cash Flow Report Appendix 4C	PRICE SENSITIVE	26/04/22	250.36KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	26/04/22	137.32KB	Share
BIT	$1.56M R&D Rebate Received	PRICE SENSITIVE	05/04/22	147.99KB	Share
BIT	BIT225 Effectiveness Against COVID-19 in Animals	PRICE SENSITIVE	17/03/22	214.51KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/22	630.82KB	Share
BIT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	135.98KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/01/22	248.82KB	Share
BIT	BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS	PRICE SENSITIVE	25/11/21	594.07KB	Share
BIT	COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS	PRICE SENSITIVE	01/11/21	157.65KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/10/21	140.11KB	Share
BIT	Quarterly Cash Flow Report	PRICE SENSITIVE	28/10/21	155.44KB	Share
BIT	Full Year Statutory Accounts and Preliminary Final Report	PRICE SENSITIVE	27/08/21	951.58KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	30/07/21	141.42KB	Share
BIT	Quarterly Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/21	155.38KB	Share
BIT	$1.4M R&D Tax Rebate	PRICE SENSITIVE	29/04/21	117.13KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	28/04/21	140.53KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	28/04/21	155.05KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	23/02/21	447.04KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/01/21	141.92KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/01/21	155.26KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/10/20	143.32KB	Share
BIT	Quarterly Cashflow Report	PRICE SENSITIVE	29/10/20	155.86KB	Share
BIT	Biotron Compounds Show Activity Against SARS-CoV-2 Virus	PRICE SENSITIVE	07/09/20	141.9KB	Share
BIT	Trading Halt	PRICE SENSITIVE	03/09/20	114.48KB	Share
BIT	Pause in Trading	PRICE SENSITIVE	03/09/20	115.52KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	27/08/20	677.29KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	29/07/20	141.46KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	29/07/20	155.99KB	Share
BIT	BIT225 Reverses HIV-Induced Immune Evasion	PRICE SENSITIVE	06/07/20	669.54KB	Share
BIT	Quarterly Activities Report	PRICE SENSITIVE	23/04/20	144.47KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	23/04/20	164.52KB	Share
BIT	R&D Tax Refund Received	PRICE SENSITIVE	19/03/20	111.09KB	Share
BIT	BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS	PRICE SENSITIVE	12/03/20	747.75KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	1.73MB	Share
BIT	Biotron to Test its Compounds Against Coronavirus	PRICE SENSITIVE	06/02/20	226.09KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	24/01/20	702.24KB	Share
BIT	Response to ASX Price Query	PRICE SENSITIVE	23/01/20	620.57KB	Share
BIT	Biotron Secures $5.1 Million Underwriting Agreement	PRICE SENSITIVE	08/11/19	228.04KB	Share
BIT	Presentation to Investors	PRICE SENSITIVE	31/10/19	980.29KB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	21/10/19	702.34KB	Share
BIT	Appointment of International Advisory Board for BIT225	PRICE SENSITIVE	01/10/19	125.89KB	Share
BIT	Full Year Statutory Accounts	PRICE SENSITIVE	29/08/19	1.08MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/19	702.33KB	Share
BIT	Presentation at BIO 2019	PRICE SENSITIVE	07/06/19	6.64MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	11/04/19	705.54KB	Share
BIT	Half Yearly Report and Accounts	PRICE SENSITIVE	20/02/19	1.72MB	Share
BIT	Appendix 4C - quarterly	PRICE SENSITIVE	18/01/19	690.62KB	Share

BIT Quarterly Activities/Appendix 4C Cash Flow Report
29/07/25	PRICE SENSITIVE	365.37KB	Share
BIT Hepatitis B Virus Program Update
24/06/25	PRICE SENSITIVE	138.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/04/25	PRICE SENSITIVE	349.8KB	Share
BIT Rights Issue Closed
08/04/25	PRICE SENSITIVE	133.63KB	Share
BIT Replacement Prospectus
12/03/25	PRICE SENSITIVE	385.48KB	Share
BIT Response to ASX Query Letter
12/03/25	PRICE SENSITIVE	374.05KB	Share
BIT Supplementary Prospectus
05/03/25	PRICE SENSITIVE	68.87KB	Share
BIT Response to ASX Aware Query
04/03/25	PRICE SENSITIVE	1.06MB	Share
BIT Prospectus
03/03/25	PRICE SENSITIVE	480.48KB	Share
BIT Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	766.57KB	Share
BIT Renounceable Rights Issue
28/02/25	PRICE SENSITIVE	162.83KB	Share
BIT Updated Appendix 4C
03/02/25	PRICE SENSITIVE	169.95KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/01/25	PRICE SENSITIVE	393.34KB	Share
BIT Agreement with C14 Consulting Group
27/11/24	PRICE SENSITIVE	168.55KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/10/24	PRICE SENSITIVE	1.07MB	Share
BIT $1.8M R&D Rebate Received
14/10/24	PRICE SENSITIVE	399.28KB	Share
BIT Response to ASX Aware Query
25/09/24	PRICE SENSITIVE	1.5MB	Share
BIT BIT225-012 PHASE 2 COVID-19 CLINICAL TRIAL
06/09/24	PRICE SENSITIVE	540.68KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
30/08/24	PRICE SENSITIVE	1.41MB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	1.01MB	Share
BIT BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
19/06/24	PRICE SENSITIVE	711.16KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
26/04/24	PRICE SENSITIVE	1MB	Share
BIT POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
05/04/24	PRICE SENSITIVE	670.99KB	Share
BIT Response to ASX Price Query
27/03/24	PRICE SENSITIVE	453.67KB	Share
BIT Half Yearly Report and Accounts
27/02/24	PRICE SENSITIVE	603.88KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/24	PRICE SENSITIVE	277.88KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	1.03MB	Share
BIT Response to ASX Price Query
29/09/23	PRICE SENSITIVE	712.55KB	Share
BIT Response to ASX Price Query
11/09/23	PRICE SENSITIVE	665.15KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
25/08/23	PRICE SENSITIVE	1.05MB	Share
BIT COMPLETION OF PHASE 2 COVID CLINICAL TRIAL
16/08/23	PRICE SENSITIVE	312.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	475.77KB	Share
BIT Second Site Approved for Phase 2 Covid-19 Trial
12/05/23	PRICE SENSITIVE	89.11KB	Share
BIT Commencement Phase 2 Covid-19 Clinical Trial
04/05/23	PRICE SENSITIVE	144.72KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	1.01MB	Share
BIT Completion of Phase 2 HIV-1 Clinical Trials
09/03/23	PRICE SENSITIVE	403.58KB	Share
BIT International Presentation of BIT225 COVID-19 Data
21/02/23	PRICE SENSITIVE	824.33KB	Share
BIT Half Yearly Report and Accounts
17/02/23	PRICE SENSITIVE	794.46KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	436.71KB	Share
BIT Rights Issue Closed
24/11/22	PRICE SENSITIVE	174.24KB	Share
BIT Supplementary Prospectus
24/11/22	PRICE SENSITIVE	139.65KB	Share
BIT $1.43M R&D rebate received
18/11/22	PRICE SENSITIVE	148.2KB	Share
BIT Commencement of Rights Trading - BITRC
31/10/22	PRICE SENSITIVE	128.29KB	Share
BIT Prospectus
27/10/22	PRICE SENSITIVE	683.43KB	Share
BIT Renounceable Issue
27/10/22	PRICE SENSITIVE	190.28KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
24/10/22	PRICE SENSITIVE	422.98KB	Share
BIT Second BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
04/10/22	PRICE SENSITIVE	181.16KB	Share
BIT Bit225 Covid-19 Human Study Commenced
14/09/22	PRICE SENSITIVE	175.41KB	Share
BIT BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited
23/08/22	PRICE SENSITIVE	154.11KB	Share
BIT Full Year Statutory Accounts and Appendix 4E
19/08/22	PRICE SENSITIVE	670.98KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/22	PRICE SENSITIVE	1.04MB	Share
BIT POSITIVE FDA GUIDANCE FOR COVID-19 CLINICAL PROGRAM
30/05/22	PRICE SENSITIVE	130.47KB	Share
BIT BIT225 EFFECTIVE AGAINST ESTABLISHED SARS-CoV-2 IN ANIMALS
02/05/22	PRICE SENSITIVE	353.01KB	Share
BIT Quarterly Cash Flow Report Appendix 4C
26/04/22	PRICE SENSITIVE	250.36KB	Share
BIT Quarterly Activities Report
26/04/22	PRICE SENSITIVE	137.32KB	Share
BIT $1.56M R&D Rebate Received
05/04/22	PRICE SENSITIVE	147.99KB	Share
BIT BIT225 Effectiveness Against COVID-19 in Animals
17/03/22	PRICE SENSITIVE	214.51KB	Share
BIT Half Yearly Report and Accounts
23/02/22	PRICE SENSITIVE	630.82KB	Share
BIT Quarterly Activities/Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	135.98KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
28/01/22	PRICE SENSITIVE	248.82KB	Share
BIT BIOTRON DRUG EFFECTIVE AGAINST COVID-19 IN ANIMALS
25/11/21	PRICE SENSITIVE	594.07KB	Share
BIT COMMENCEMENT OF TWO PIVOTAL BIT225 CLINICAL TRIALS
01/11/21	PRICE SENSITIVE	157.65KB	Share
BIT Quarterly Activities Report
28/10/21	PRICE SENSITIVE	140.11KB	Share
BIT Quarterly Cash Flow Report
28/10/21	PRICE SENSITIVE	155.44KB	Share
BIT Full Year Statutory Accounts and Preliminary Final Report
27/08/21	PRICE SENSITIVE	951.58KB	Share
BIT Quarterly Activities Report
30/07/21	PRICE SENSITIVE	141.42KB	Share
BIT Quarterly Appendix 4C Cash Flow Report
30/07/21	PRICE SENSITIVE	155.38KB	Share
BIT $1.4M R&D Tax Rebate
29/04/21	PRICE SENSITIVE	117.13KB	Share
BIT Quarterly Activities Report
28/04/21	PRICE SENSITIVE	140.53KB	Share
BIT Appendix 4C - quarterly
28/04/21	PRICE SENSITIVE	155.05KB	Share
BIT Half Yearly Report and Accounts
23/02/21	PRICE SENSITIVE	447.04KB	Share
BIT Quarterly Activities Report
29/01/21	PRICE SENSITIVE	141.92KB	Share
BIT Quarterly Cashflow Report
29/01/21	PRICE SENSITIVE	155.26KB	Share
BIT Quarterly Activities Report
29/10/20	PRICE SENSITIVE	143.32KB	Share
BIT Quarterly Cashflow Report
29/10/20	PRICE SENSITIVE	155.86KB	Share
BIT Biotron Compounds Show Activity Against SARS-CoV-2 Virus
07/09/20	PRICE SENSITIVE	141.9KB	Share
BIT Trading Halt
03/09/20	PRICE SENSITIVE	114.48KB	Share
BIT Pause in Trading
03/09/20	PRICE SENSITIVE	115.52KB	Share
BIT Full Year Statutory Accounts
27/08/20	PRICE SENSITIVE	677.29KB	Share
BIT Quarterly Activities Report
29/07/20	PRICE SENSITIVE	141.46KB	Share
BIT Appendix 4C - quarterly
29/07/20	PRICE SENSITIVE	155.99KB	Share
BIT BIT225 Reverses HIV-Induced Immune Evasion
06/07/20	PRICE SENSITIVE	669.54KB	Share
BIT Quarterly Activities Report
23/04/20	PRICE SENSITIVE	144.47KB	Share
BIT Appendix 4C - quarterly
23/04/20	PRICE SENSITIVE	164.52KB	Share
BIT R&D Tax Refund Received
19/03/20	PRICE SENSITIVE	111.09KB	Share
BIT BIT225 RESTORES IMMUNE FUNCTION IN HIV-1 INFECTIONS
12/03/20	PRICE SENSITIVE	747.75KB	Share
BIT Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	1.73MB	Share
BIT Biotron to Test its Compounds Against Coronavirus
06/02/20	PRICE SENSITIVE	226.09KB	Share
BIT Appendix 4C - quarterly
24/01/20	PRICE SENSITIVE	702.24KB	Share
BIT Response to ASX Price Query
23/01/20	PRICE SENSITIVE	620.57KB	Share
BIT Biotron Secures $5.1 Million Underwriting Agreement
08/11/19	PRICE SENSITIVE	228.04KB	Share
BIT Presentation to Investors
31/10/19	PRICE SENSITIVE	980.29KB	Share
BIT Appendix 4C - quarterly
21/10/19	PRICE SENSITIVE	702.34KB	Share
BIT Appointment of International Advisory Board for BIT225
01/10/19	PRICE SENSITIVE	125.89KB	Share
BIT Full Year Statutory Accounts
29/08/19	PRICE SENSITIVE	1.08MB	Share
BIT Appendix 4C - quarterly
30/07/19	PRICE SENSITIVE	702.33KB	Share
BIT Presentation at BIO 2019
07/06/19	PRICE SENSITIVE	6.64MB	Share
BIT Appendix 4C - quarterly
11/04/19	PRICE SENSITIVE	705.54KB	Share
BIT Half Yearly Report and Accounts
20/02/19	PRICE SENSITIVE	1.72MB	Share
BIT Appendix 4C - quarterly
18/01/19	PRICE SENSITIVE	690.62KB	Share

REFRESH

1 2

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 0.3¢		Change 0.001(25.0%)		Mkt cap ! $3.318M

Open	High	Low	Value	Volume
0.3¢	0.3¢	0.3¢	$500	200K

Buyers (Bids)

No.	Vol.	Price($)
47	36018629	0.2¢

Sellers (Offers)

Price($)	Vol.	No.
0.3¢	15608555	20

View Market Depth

No.	Vol.	Price($)
47	36018629	0.002
32	93302000	0.001
0	0	0.000
0	0	0.000
0	0	0.000

Price($)	Vol.	No.
0.003	15608555	20
0.004	16987080	16
0.005	6690600	5
0.006	1200000	2
0.007	572733	2

Last trade - 15.15pm 31/07/2025 (20 minute delay)


Last 0.2¢		Change 0.001 ( 20.0 %)
Open	High	Low	Volume
0.2¢	0.2¢	0.2¢	26000
Last updated 14.58pm 31/07/2025 ?

BIT (ASX) Chart

BIOTRON LIMITED - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories

BIOTRON LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories

Corporate Spotlight
Not Yet Available